5,271 trials (keyword fallback)
B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia
Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…
Chronic Lymphocytic Leukemia
Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) — 0.89 proportion of participants
Safety and Tolerability · Compare SHINGRIX Vaccine Response Rates · Chronic Lymphocytic Leukemia (CLL)
Primary: Number of Participants With Varicella Zoster Virus (VZV) Seroprotective Titer — 43; 11; 9 Participants
Hepatitis · Safety and Tolerability
Primary: Number of Participants With HEPLISAV-B Seroprotective Titer (Anti-HBs 10mIU/mL) — 0; 1; 9 Participants
Small Lymphocytic Lymphoma · CLL (Chronic Lymphocytic Leukemia)
Primary: Progression Free Survival Rate 2 Years After Initiation of Induction Therapy — 14; 9 Participants
Chronic Lymphocytic Leukemia
Primary: Complete Response Rate — 36 percentage of patients
Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Primary: Phase I: Maximum Tolerated Dose (MTD) — NA mg
Chronic Lymphocytic Leukemia · CLL
Primary: Overall Response Rate (ORR) — 25 Participants
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic · Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or · Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
Primary: Number of Participants Contributing to the Overall Response Rate — 34 participants
Chronic Lymphocytic Leukemia · Prolymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma
Primary: Overall Survival — 34 Participants
Chronic Lymphocytic Leukemia
Primary: Overall Objective Response — 3 participants who responded
Indolent Non-Hodgkin's Lymphoma · Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events — 298; 302 number of adverse events
Leukemia
Primary: Maximum Tolerated Dose (MTD) Oxaliplatin — 25 mg/m^2